0000008063-25-000086
SEC filingAerospace sales growth driven by commercial transport and military markets, but losses on debt and UK patent dispute weigh on net income.
For the nine months ended September 27, 2025, consolidated sales increased 6.0% to $622.1 million from $586.9 million in the prior-year period, driven primarily by the Aerospace segment. Gross profit rose 12.6% to $178.2 million, with gross margin expanding 160 bps to 28.6%, reflecting favorable product mix and pricing initiatives. Net loss narrowed significantly to $0.3 million ($0.01 per diluted share) from $13.4 million ($0.38 per diluted share), as higher gross profit and lower interest expense ($8.7M decline) more than offset a $25.6M increase in loss on settlement of debt. SG&A increased $3.7 million to $104.4 million, including a $9.7 million reserve adjustment for a UK patent dispute, partially offset by lower litigation expenses. R&D spending decreased $7.2 million to $32.8 million due to project timing. The effective tax rate shifted from (58.5)% to 14.4%, primarily from a valuation allowance reversal related to research and development costs under the One Big Beautiful Bill Act (OBBBA). Operating cash flow improved to $47.2 million from $4.1 million, aided by higher cash earnings and lower working capital.
Aerospace segment sales grew 11.5% to $577.7 million, with commercial transport up 12.7% and military aircraft up 38.9%, while general aviation declined 16.1%. Operating profit increased 56.7% to $71.5 million, with margin expanding to 12.4% from 8.8%, reflecting volume leverage, pricing, and $7.3 million lower litigation expenses, offset by $9.7 million UK dispute charges and $6.5 million in simplification costs. Test Systems sales dropped 35.5% to $44.3 million, driven by lower radio test set sales and $8.3 million in revenue revisions on mass transit contracts. Operating loss widened slightly to $8.9 million (margin -20.2% vs. -12.3%), as $8.8 million in unfavorable cost revisions masked restructuring savings.
Management expects cash flow from operations to fund operations, including further UK dispute payments. The company emphasizes compliance with covenants under the new $300M revolving credit facility (entered October 2025). Key risks include supply chain pressures, tariffs (estimated $4M-$7M impact YTD), OEM production rates, and a potential prolonged U.S. government shutdown. The OBBBA is expected to favorably impact tax rates going forward. No specific revenue or earnings guidance is provided, but the company highlights growth opportunities in commercial and military aerospace, while Test Systems faces lumpy order patterns and margin pressure from fixed-cost underabsorption.
Cash and cash equivalents stood at $13.5M at quarter-end, with an additional $6.1M restricted under the ABL facility, totaling $19.6M. Total debt increased sharply to $334.0M from $168.7M at year-end 2024, driven by the issuance of $225.0M of 2031 Convertible Notes and $85.0M of ABL borrowings, partially offset by the $285.8M repurchase of $132M principal of 2030 Notes. Shareholders' equity fell to $108.9M from $256.1M, largely due to the equity component of the debt repurchase and capped call transactions. Inventory remained stable at $197.3M.
Total backlog (remaining performance obligations) was $646.7M, with $479.2M expected to be recognized within twelve months. No other material purchase commitments were disclosed. Contract liabilities (deferred revenue) were $27.8M, slightly down from $28.2M at year-end. Legal obligations include $17.5M in German patent reserves (non-current) and $1.0M for UK legal costs (current).
The company did not repurchase any common shares during the period; $41.5M remains authorized under the buyback program. The ATM equity program has $8.2M remaining capacity. No dividends are paid. Capital expenditures totaled $19.9M for the nine months, primarily in the Aerospace segment ($19.3M). Debt management was active: the $225.0M 2031 zero-coupon notes were issued, with net proceeds used to repurchase $132M principal of 5.5% 2030 notes at a premium, resulting in a $32.6M loss on settlement. Capped call transactions cost $26.9M. The ABL facility had $85.0M outstanding with $112.3M available. Subsequent to quarter-end, the ABL was replaced with a $300M cash flow revolver.
Aerospace segment sales rose 11.5% to $577.7M, with operating profit of $71.5M (12.4% margin), improving from 8.8% a year ago. Growth was driven by commercial transport ($432.3M, +13%) and military ($88.3M, +39%), partially offset by declines in general aviation and other. Test Systems sales fell 35.5% to $44.3M, with an operating loss of $8.9M (-20.2% margin), due to lower government & defense revenue ($44.3M vs $68.8M). Segment assets: Aerospace $544.5M, Test Systems $112.8M, Corporate $24.9M. Depreciation and amortization totaled $16.1M, with Aerospace accounting for $13.7M.
Net loss of $0.3M was offset by significant non-cash adjustments: depreciation & amortization ($16.1M), provisions for losses ($6.1M), equity-based compensation ($5.3M), simplification charges ($6.2M), loss on debt settlement ($32.6M), and deferred tax benefit ($1.1M). Operating cash flow of $47.2M benefited from working capital improvements: accounts receivable provided $5.2M, inventories used $7.1M, accounts payable provided $8.3M, accrued expenses used $14.7M, and income taxes paid $11.5M. The large income tax payment reflects a one-time outflow. Capital expenditures increased sharply to $19.9M from $5.2M, indicating investment in growth. Financing activities included $225M proceeds from convertible debt and $86.1M from long-term debt, offset by $285.8M partial repurchase of 2030 notes and $26.9M for capped call transactions, resulting in net financing cash outflow of $22.6M. Overall, cash flow quality is strong due to non-cash charges and working capital management, but capex intensity is rising.